

# Rohit Loomba

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4715673/rohit-loomba-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45  
papers

944  
citations

15  
h-index

30  
g-index

61  
ext. papers

2,157  
ext. citations

9.8  
avg, IF

5.67  
L-index

#	Paper	IF	Citations
45	Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> , 18, 223-238	24.2	228
44	Advances in non-invasive assessment of hepatic fibrosis. <i>Gut</i> , <b>2020</b> , 69, 1343-1352	19.2	68
43	Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 645-656	6.1	46
42	Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 183-193	6.1	42
41	Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis. <i>Journal of Immunology</i> , <b>2018</b> , 201, 3017-3035	5.3	41
40	Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 1149-1159	6.1	40
39	Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. <i>Hepatology</i> , <b>2020</b> , 72, 1219-1229	11.2	39
38	Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 1305-1320	6.1	38
37	Collagen biology and non-invasive biomarkers of liver fibrosis. <i>Liver International</i> , <b>2020</b> , 40, 736-750	7.9	38
36	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> ,	24.2	37
35	NAFLD: Reporting Histologic Findings in Clinical Practice. <i>Hepatology</i> , <b>2021</b> , 73, 2028-2038	11.2	31
34	Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 144-158	6.1	26
33	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 20-30	13.4	24
32	The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH. <i>Hepatology</i> , <b>2021</b> , 73, 126-143	11.2	22
31	MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Gut</i> , <b>2021</b> , 70, 1946-1953	19.2	18
30	Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 844-854	6.1	15
29	Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 1150-1161	6.1	15

28	Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. <i>Annals of Laboratory Medicine</i> , <b>2021</b> , 41, 16-24	3.1	14
27	Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor $\alpha$ modulator (SPPARM $\alpha$ ) versus placebo in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 1263-1277	6.1	14
26	Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. <i>Hepatology</i> , <b>2020</b> , 72, 1819-1837	11.2	12
25	Links between gut microbiome composition and fatty liver disease in a large population sample. <i>Gut Microbes</i> , <b>2021</b> , 13, 1-22	8.8	12
24	Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 1100-1111	6.1	11
23	Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 1030-1037	6.1	10
22	Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. <i>Gut</i> , <b>2021</b> ,	19.2	10
21	Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis. <i>Therapeutic Advances in Gastroenterology</i> , <b>2020</b> , 13, 1756284820923904	4.7	9
20	Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. <i>Hepatology</i> , <b>2021</b> , 73, 548-559	11.2	9
19	Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 880-889	6.1	9
18	Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality.. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> ,	6.1	8
17	Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. <i>Nature Medicine</i> , <b>2021</b> , 27, 1825-1835	50.5	8
16	Have incidence rates of liver cancer peaked in the United States?. <i>Cancer</i> , <b>2020</b> , 126, 3151-3155	6.4	7
15	MRE plus FIB-4 (MEFIB) versus FAST in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Hepatology</i> , <b>2021</b> ,	11.2	6
14	NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH. <i>Hepatology</i> , <b>2021</b> ,	11.2	5
13	A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques.. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabg8116	17.5	5
12	The impact of genetic risk on liver fibrosis in non-alcoholic fatty liver disease as assessed by magnetic resonance elastography. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 68-77	6.1	5
11	Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project.. <i>Nature Medicine</i> , <b>2022</b> ,	50.5	4

10	Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis.. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabg8117	17.5	3
9	Elevated Glycated Hemoglobin Is Associated With Liver Fibrosis, as Assessed by Elastography, in a Population-Based Study of Mexican Americans. <i>Hepatology Communications</i> , <b>2020</b> , 4, 1793-1801	6	3
8	Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study.. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> ,	6.1	3
7	Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD. <i>Hepatology</i> , <b>2021</b> , 74, 2241-2250	11.2	2
6	Review article: current and emerging therapies for the management of cirrhosis and its complications.. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> ,	6.1	2
5	Non-invasive Risk Stratification for NAFLD Among Living Liver Donor Candidates: A Proposed Algorithm. <i>Liver Transplantation</i> , <b>2021</b> ,	4.5	1
4	Financial Hardship From Medical Bills Among Adults With Chronic Liver Diseases: National Estimates From the United States. <i>Hepatology</i> , <b>2021</b> , 74, 1509-1522	11.2	0
3	Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD.. <i>Radiology</i> , <b>2022</b> , 211131	20.5	0
2	Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease.. <i>Therapeutic Advances in Gastroenterology</i> , <b>2022</b> , 15, 17562848221093869	4.7	0
1	Letter: probiotics? Yes, but which ones? AuthorsSreply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 968	6.1	